Exclusive: ADC startup Mythic recruits Jazz exec to lead company; Dyne’s CEO shuffle

George Eliades

Mythic Therapeutics has gone more than a year and a half without a CEO.

That’s changing on April 1, as George Eliades will join the Waltham, MA-based antibody-drug conjugate biotech. Eliades is coming from Jazz Pharmaceuticals, where he’s served as senior vice president of corporate development and chief transformation officer for the past three and a half years.

In the interim, Mythic’s CEO duties were shared among chief scientist Brian Fiske, COO Sandra Poole and chief development officer Gilles Gallant, according to a press release.

Eliades said he was initially searching for board roles when he first connected with the company. “To be perfectly honest, I wasn’t looking for a job,” he said. “As I learned more and more about the technology, I got very excited about it.”

Antibody-drug conjugates, or ADCs for short, have been perhaps the hottest…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks